Lung Cancer
Recent findings in lung cancer described by researchers from Spain, Greece and the South Korea
Published in Cancer Weekly, August 29th, 2006
Study 1: Lung cancer treated by biweekly regimen of cisplatin, gemcitabine and vinorelbine resulted in a high rate of response and comparatively low toxicity, but no survival benefit.
"Improving chemotherapeutic efficacy in non-small cell lung cancer (NSCLC) will require the development of new strategies to better use currently available agents. [The study's aim was] to assess the efficacy and safety of a biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer. Patients with selected stage IIIb (pleural effusion)/stage...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-08-29)
More Articles from Cancer Weekly
- Cancer Therapy
Ambitious research program in pharmacogenetics aims to individualize cancer treatment - Colorectal Adenoma
Advanced colorectal adenoma recurrence risk reduced with high dry bean intake - Ovarian Cancer
Ovarian cancer risk potentially reduced with paracetamol use - Pancreatic Cancer
Pancreatic carcinogenesis possibly prevented by targeting nuclear factor kappa B - Acoustic Neuromas
House Clinic offers Gamma Knife technology as treatment for acoustic neuromas - Acute Myeloid Leukemia
Acute myeloid leukemia survival improved with high-dose cytosine arabinoside - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
